INVEST IN DE3 TODAY!
Our technology is currently capable of detecting and eliminating pathogens as small as bacteria, algae, and some larger viruses. We are currently looking to expand our capabilities to identify even smaller viruses such as COVID-19.
The pathogen detection industry is predicted to grow to $5.7 billion by 2025, and we already have interest across a wide variety of use cases, from governmental agencies to several Fortune 1000 companies, including automotive, household and petrochemical, and pet distribution companies.*
Our leadership experienced devastation and loss due to the global pandemic. With 15+ years of research development and over 25 filed patent applications, we are harnessing AI to prevent the contamination and pandemics of the future.
We are an AI company that can detect, identify, and eliminate pathogens and contaminants in targeted areas in soil, air, water, waste, and on hard surfaces. We enable clean-up efforts to be swift, targeted, and precise while avoiding the overuse and underuse of toxic remediation substances with our Rhamnolipid biosurfactant applications. With over 25 pending patents and interest from governmental agencies and Fortune 100 companies, we are ready to build a safer, healthier, and cleaner world.
At De3, we aim to save lives through AI-enabled pathogen detection. By eliminating human error and reducing the time required between sampling and identification, we can reduce exposure to harmful pathogens and contaminants. Meanwhile, our ecologically friendly, naturally-occurring biosurfactant known as Rhamnolipid, can eliminate the detected pathogens and enables contaminant remediation without harmful toxins. In a study, Application of Environment-Friendly Rhamnolipids against Transmission of Enveloped Viruses Like SARS-CoV2 (also known as Covid), Rhamnolipid products were investigated as disinfectants against enveloped viruses, such as bovine coronavirus and herpes simplex virus 1 (HSV-1). Findings indicated that the Rhamnolipid coated on masks or plastic surfaces can reduce the emission of SARS-CoV2 from an infected person and stop the spread of SARS-CoV2 (Source).
Together, these technologies can work together to make our planet healthier and safer for plants, animals, and humans.
The Problem & Our solution
Current pathogen and contaminant detection is a time-consuming, lab-based process subject to delays and human error. This can cause delays and halts to business operations and loss of revenues as businesses await results and decontamination efforts. Meanwhile, the only way to remediate environments of harmful pathogens and contaminants is to use toxic synthetic chemicals. In a world reshaped by the global pandemic, we are in urgent need of better solutions.
We can detect pathogens on location and in real-time using advanced software/hardware applications and AI. First, we place collected samples beneath a microscope which uses computer language systems, machine learning, and computer vision to identify on-the-spot which harmful pathogens are present. Then, we can prepare non-toxic Rhamnolipid solutions known to eliminate and remediate the most robust of the pathogens and contaminants present. Utilizing our processing and manufacturing trade secrets, proprietary bacteria strains, and future AI implementation, we can create precise calculations of ratios of Mono-rhamnolipid to Di-rhamnolipid, their carriers, and their dilutions for specific applications.
the market & Our Traction
The global pathogen detection market is expected to reach $5.7 Billion by 2025, growing at a CAGR of 12.2% (Source). Meanwhile, the global biosurfactants market is projected to grow from $4.18 billion in 2022 to $6.04 billion by 2029 at a CAGR of 5.4% (Source). With the increasing demand for green and non-toxic products, the rhamnolipid market alone is expected to increase by $35.86 million from 2021 to 2026 at a CAGR of 9.06% (Source).
We have filed more than 25 pending patents for our technology. Our rhamnolipid biosurfactant is tested and registered with the Federal and Florida EPA. Most recently, we developed “Project Claire,” a more automated version of our pathogen detection system that can be integrated with drones, robots, and liquid tube systems for faster sample collection and detection.
Now, more than ever, we need to get smarter about our approach to pathogens, contaminants, and preserving a healthy environment around us. With the introduction of new mutations of the COVID virus every year since 2019, the risk posed by future evolutions of viruses and bacteria has never been more evident. However, coating our fragile ecosystems with potentially harmful synthetic chemicals to protect ourselves from dangerous pathogens is not the answer. De3 provides a third option, an intelligent and targeted approach to pathogen detection and elimination. We are eliminating the reactionary “spray and pray” methods of the past which solved the immediate problem but were harmful to the environment in the long run. We aim to replace toxic chemicals with natural and safe alternatives. The applications are nearly infinite. From your backyard to the International Space Station.
We are at the forefront of global movements to detect and remove infections and outbreaks before they spread, reverse pollution and contaminants while banning harmful synthetic chemicals, using computer software systems, hardware, and AI to improve lives. Several Fortune 1000 companies have seen our use cases and have expressed interest in our applications and future potential.
With your support, we will continue to research and develop new and improved systems and services, with the goal of becoming the go-to leaders of automated pathogen and contaminant detection systems and natural biosurfactants.
De3 has developed patent-pending, AI-powered technology enabling the real-time detection, identification, and elimination of pathogens and contaminants. The Company is continuing to enhance its intellectual property portfolio with continued developments and patent protection filings.
Keith has self-funded the company and technologies without incurring debt. He has researched, developed and filed over 24 patents with the USPTO and WIPO for artificial intelligence, machine learning, software programs and biosurfactant applications. He is the first person to be granted a Rhamnolipid biofilm patent from the USPTO which is at the core of DE3’s technology.
He started his career on Wall Street after earning a Bachelor of Science degree in Mathematics from Northeastern University, and capitalized on his financial acumen and entrepreneurial spirit to found and successfully exit four companies before founding DE3.
Dr. Mehul Patel
Dr. Patel graduated from Cornell University studying Policy Analysis and Management with a concentration in Health Policy and completed his medical school and training at SUNY Downstate College of Medicine. Dr. Patel is a New York State licensed physician who focuses on the importance of health, fitness, nutrition, and education. Dr. Patel brings a passion for startup firms and serves as an advisor for multiple companies. He serves as a CAAAN admissions member for his alma mater Cornell University. As a physician, he has focused his energy helping his patients and clients optimize their potential through a company he founded doing business as, Prixcel Health & Education Consulting.
Timothy Sierzega Rouse
He brings a background as a Mechanical Engineer (BS) and as an Aerospace Engineer (BS and MS) to bear, as well as significant experience developing Artificial Intelligence solutions and leading AI Engineers / Data Scientists. He has worked in R&D, managing efforts and personally carrying them out, through to developing and deploying custom solutions. From Aviation to Medicine to Tech to Retail, a wide variety of experience and lessons learned are utilized to bring the team and our capabilities to the next level.
Francis Joe Trebbe III
Alyssa Nichole Cruz
Director of Client Services
She holds several certifications, including a CompTIA Security+ CE Certification, is a Splunk Core Certified User, and an EC-Council Certified Ethical Hacker.
Daniel Ramon Rojas
Director of Operations
Daniel has a Computer Programming Specialist Certification and has a background in computer programming and web development.
Steven Joseph Brownstein
Director of IT
He has served in the US Army in an IT capacity, and has also held technical positions with Lockheed Martin, Borland-Groover Clinic, and the USDA.
Jesse Edmond Fabish
Director of Debt and Equity Financing
Jesse will drive both the capital raises required to scale the business, and the revenue generation from customers. He brings experience as an Engineering Apprentice with the US Air Force, and most recently served as an Engineering Supervisor for FDH, a civil engineering firm in Raleigh, North Carolina.
Maximum Number of Shares Offered subject to adjustment for bonus shares
Most Recent Fiscal Year-End
Prior Fiscal Year-End
Cash & Cash Equivalents
Revenue & Sales
Costs of Goods Sold
*Maximum number of shares offered subject to adjustment for bonus shares. See Bonus info below.
Friends and Family Early Birds
Invest within the 48 hours and receive 15% bonus shares
Super Early Bird Bonus
Invest within the first week and receive 10% bonus shares
Early Bird Bonus
Invest within the three weeks and receive 5% bonus shares
$25,000 | Tier 1
Invest up to $25,000 and receive a 3% Bonus of Series A Common Stock non-voting shares.
$50,000 | Tier 2
Invest up to $50,000 and receive a 5% Bonus of Series A Common Stock non-voting shares.
$100,000 | Tier 3
Invest up to $100,000 and receive a 10% Bonus of Series A Common Stock non-voting shares.
*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed.
De3 will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.
This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Class A Common Stock at $2.50 / share, you will receive 110 shares of Class A Common Stock, meaning you'll own 110 shares for $250. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.
This 10% Bonus is only valid during the investors' eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.
Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus in addition to the aforementioned bonus.
Hello StartEngine community,
There is a few days left in our campaign and to invest in your health and the environment. With the recent train derailments and chemicals spills happening around the country, recent fungal and hepatitis outbreaks, and harmful algae blooms hitting Florida, there is continued proof that new ways of detection and cleanup are needed in our local communities and environment.
Take this final opportunity to help jumpstart the positive change to help create better systems to detect outbreaks with AI before they spread and to cleanup the environment with natural rhamnolipid biosurfactants. Our applications have great potential and use cases against many of these types of scenarios. With the way the country is currently headed, these events will become more commonplace and the need for our applications will increase.
Invest and buy shares today in De3 Inc.
Learn more at de3.ai.
The use of cheap, synthetic, and petroleum-based chemicals is prevalent in essentially every industry around the world. These chemicals are toxic and cause harmful effects to people’s health and their environment, but they are still widely used as they are relatively inexpensive. Many long-term health and environmental effects are also disregarded until a crisis arises. Chemical suppliers care more about the number of sales of their products now versus the health of their customers and the surrounding areas later. We believe there doesn’t need to be a trade-off in effectiveness and toxicity versus price. That is where a natural and non-toxic chemical called rhamnolipid can be the solution.
Rhamnolipids are produced naturally in the environment. The bacteria pseudomonas aeruginosa is found everywhere from indoors to outdoors, from countertops in our kitchen to lakes, streams, and in soil. The chemical rhamnolipid is secreted by the bacteria to protect itself and survive. Harnessing these properties, we can produce rhamnolipid by a fermentation process similar to those used to produce beer or other fermented products. Unique strains from our library of bacteria are added to a fermentation tank and provided a nutrient source, such as an oil. Using unique processes, properly controlled conditions, and manufacturing trade secrets, low-cost rhamnolipids can be produced in industrial quantities. The rhamnolipids are extracted, processed to remove any residual bacteria, purified, and the resultant mixture diluted into a final product. The amount and mixture of rhamnolipid material in the final solution can be precisely controlled to specific ratios, mixtures, dilutions, and carriers. The rhamnolipid can be further refined to produce certain foaming characteristics and mixed according to specific applications, such as wetting agents for the agricultural industry. Our goal is to build a large-scale manufacturing facility to provide industrial-scale quantities of rhamnolipid biosurfactants to meet the demand of businesses worldwide.
Utilizing artificial intelligence, we can further increase the effectiveness of rhamnolipid. AI can provide recommendations and application-specific data to better refine the rhamnolipid processes and final product. If a hazard is detected in the field, the AI can recommend a solution based on that information. Time, effort, and funds can be saved in the research, development, testing, manufacturing, and application of rhamnolipid with the power of AI.
We have spent years in research, development, and testing of our rhamnolipid biosurfactants. Our rhamnolipid, RhamnoWash 10, is a naturally derived biosurfactant, consisting of lipid and rhamnose sugar molecules. On August 3, 2015, the U.S. Environmental Protection Agency (EPA) issued a letter to us regarding the listing of RhamnoWash 10™ as a Surface Washing Agent on the National Oil and Hazardous Substance Pollution Contingency Plan (NCP) Product Schedule maintained by the USEPA. In order to list RhamnoWash 10, technical product data was submitted to the USEPA pursuant to 40 CFR 300.915(b).
In 2004, The EPA issued a letter stating that rhamnolipid was accepted as a spray to kill pests on agricultural products in the United States. It also noted that rhamnolipid was also registered as “safe” to be ingested by humans at very low concentrations.
On February 24, 2014, we were granted approval by the Florida Department of Environmental Protection for rhamnolipid wastewater and soil washing applications. The letter indicates that the Division of Waste Management accepts Rhamnolipid Aqueous Solution for in situ bioremediation of petroleum hydrocarbons and metals in groundwater and soil.
In 2021, we were granted permission to test and take samples in the Tampa Bay by the Florida Department of Environmental Protection.
In 2018, Helen Zhang, Professor at Memorial University, successfully tested our biosurfactants via an adsorption experiment for investigating cobalt removal from soil.
"When applying rhamnolipid, by increasing the initial concentration of Co, the remaining Co in the solution increased considerably at any initial concentration of rhamnolipid. The high value range of surface tension of solutions (60-70 mN/m) shows that rhamnolipid has a high tendency of adsorption to the soil surface."
Rhamnolipid has a wide array of use cases such as:
With many more applications spanning various industries. Its natural, non-toxic properties, and “green” manufacturing process with no harmful byproducts make it a unique substance that can replace the toxic synthetic alternatives widely used today. Utilizing AI, we can further unlock its capabilities, applications, and to further refine the manufacturing process. As we grow and start to produce rhamnolipid in industrial quantities from a large-scale manufacturing facility, we can begin to phase out and replace harmful alternatives.
Join our mission to replace harmful chemicals. Invest and buy shares today in De3 Inc.
Learn more at de3.ai.
AI is quickly changing the landscape in all facets of technology, businesses, the environment, health, communications, and many other sectors. With recent pandemics, contamination disasters, and general environment and water quality concerns, the need for AI to better serve our health has been pushed to the forefront.
De3 believes that we can be that transformational change by creating technologies and applications that can directly benefit people's health and the overall landscape of the current environment while utilizing artificial intelligence. We can be that preventative measure from future health and contamination disasters while leading the change from toxic chemicals to renewable and natural rhamnolipid biosurfactants with a wide array of applications. Data, analytics, predictive analysis, and knowledge from harnessing the computational power of AI is that change.
Get a deeper dive into our AI system with Daniel Rojas as he explains some of our current and future AI capabilities. We are confident that with our technology and the increased demand for these types of applications, we will see healthy growth within the company while contributing to a healthier populace and environment.
Invest in your health and the environment around you by joining our mission and ambitious vision. Purchase your shares today.
Learn more at de3.ai and stay tuned for more updates, videos, live streams, and technology highlights.
Hello StartEngine community,
We are excited to finally go live on StartEngine and to interact with the community of investors/potential investors as we continue to grow and achieve our mission. This has been a long time coming and we are excited about our future opportunities.
Our journey began 20+ years ago when the founder, Keith Louis De Santo, first got into the rhamnolipid biosurfactant industry. He spent years on research and development, efficacy testing, EPA testing and registrations, intellectual property, partnerships with institutions (domestic and international), as a keynote speaker in biosurfactant symposiums, and many other opportunities and relationships. Given rhamnolipid's unique properties and use cases across a wide array of industries, there are endless ways to configure the end product to tackle specific needs, especially in the medical and remediation services sectors.
As artificial intelligence and machine learning began to grow during the late 2010s, the team realized that instead of manual testing of areas for potential contamination or outbreaks present and manual trial and error testing of the correct dilutions, carries, and ratios of specific rhamnolipid formulations for those scenarios, we could use the power of AI/machine learning to quickly identify and bolster our rhamnolipid applications. Testing can become faster and more automated, saving time, money, human error, and exposure to potentially hazardous material. When something is found, unique specific rhamnolipid application formulations that are most beneficial to the specific material can be recommended by the AI, leaving the guesswork and trial and error behind. AI can be used to optimize many industries and these applications are no exception.
When COVID-19 began to spread worldwide, we knew we had to find better ways of being a preventative measure and not a cure so we are not left unprepared when another widespread outbreak or contamination comes. It's not a matter of if, but when. The recent pandemic cemented our mission forward. That's what led us to where we are now. With rhamnolipid's natural and non-toxic applications coupled with AI to help detect micro-organisms and contamination, we believe we can replace toxic alternatives that are destroying our health and the environment and be the go-to preventative measure for future outbreaks.
Invest today and share with your community so we tackle these problems together and we can all benefit from a cleaner and healthier environment.
More exciting updates to come!
-The DE3 team
Members get an extra 10% shares in addition to rewards below!
3 months ago
Cancel anytime before 48 hours before a rolling close or the offering end date.
We want you to succeed and get the most out of your money by offering rewards and memberships!
Your info is your info. We take pride in keeping it that way!
Invest in over 200 start-ups and collectibles!
With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.
With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.
At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.
Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.
StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.
For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.
For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.
Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.
Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.
Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.
W Kim Colich
3 months ago